Regentis Biomaterials Ltd. (NYSE American: RGNT) announced plans to begin European surgeon training activities in the third quarter of 2026 as part of preparations for the commercial rollout of GelrinC(R), its CE Mark-approved treatment for knee cartilage lesions. The hands-on program will provide orthopedic surgeons with practical experience using the company’s cell-free implant and is expected to begin at Humanitas Research Hospital in Milan, Italy, with additional sessions planned across Europe.
The company said the training initiative is a key step in its European commercialization strategy and will be supported by a network of Centers of Excellence focused on surgeon education, clinical guidance and knowledge sharing. GelrinC is designed as a ready-to-use, single-step implant procedure for knee cartilage repair, and Regentis believes expanding physician familiarity with the technology will support adoption as the product enters broader clinical use.
The announcement underscores the importance of physician training in the adoption of novel medical devices, particularly in orthopedics where surgical technique can significantly impact patient outcomes. By investing in hands-on training programs, Regentis aims to ensure that surgeons are proficient in the GelrinC procedure, potentially reducing learning curves and improving clinical results. The company’s focus on Centers of Excellence suggests a strategic approach to building a referral network and establishing clinical evidence in real-world settings.
GelrinC addresses a significant unmet need in knee cartilage repair. According to Regentis, approximately 470,000 cases for cartilage knee repair occur annually in the U.S. alone, where no off-the-shelf treatment is currently available. The product’s cell-free, off-the-shelf nature could offer advantages over existing therapies that require cell harvesting or multiple surgical steps. The European launch follows CE Mark approval, positioning Regentis to enter a market with growing demand for minimally invasive regenerative solutions.
The training program at Humanitas Research Hospital, a renowned orthopedic center, lends credibility to the initiative and may facilitate adoption among European surgeons. As Regentis expands the program to additional sites, the company will likely gather feedback to refine its training curriculum and product positioning. Successful commercialization in Europe could also serve as a stepping stone for future regulatory submissions in other regions, including the United States.
For investors, the training milestone signals that Regentis is progressing toward revenue generation from GelrinC. The company’s focus on surgeon education may help differentiate it from competitors and build a loyal user base. However, the success of the launch will depend on factors such as reimbursement, clinical outcomes, and competitive dynamics in the knee cartilage repair market.
More information on the press release can be found at https://ibn.fm/QOWWK.
About Regentis Biomaterials: Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore health and enhance quality of life. With an initial focus on orthopedic treatments, Regentis’ Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue including inflamed cartilage and bone. Regentis’ lead product GelrinC(R), is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing the surrounding cells to regenerate the cartilage in a controlled and synchronous process. GelrinC(R) aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S. where no off-the-shelf treatment is available.
NOTE TO INVESTORS: The latest news and updates relating to RGNT are available in the company’s newsroom at https://ibn.fm/RGNT.